Uteroglobin

Drug Profile

Uteroglobin

Alternative Names: Blastokinin; CC10; CC16; CCSP; CG 100; CG 367; CG201; CG459; Clara cell 10 kDa protein; Claragen; PCB-binding protein; Recombinant human CC10 protein; Recombinant human Clara cell 10 kDa protein; Recombinant human secretoglobin 1A1; rhCC10; SCGB1A1; Urine protein-1

Latest Information Update: 25 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Brigham and Womens Hospital; Therabron Therapeutics; Tufts-New England Medical Center
  • Class Anti-inflammatories; Recombinant proteins; Respiratory stimulants
  • Mechanism of Action Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia; Bronchiolitis obliterans
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchopulmonary dysplasia
  • Phase I/II Sinusitis
  • Preclinical Acute lung injury; Asthma; Bronchiolitis obliterans; Burns; Chronic obstructive pulmonary disease; Influenza virus infections; Pneumonia; Respiratory distress syndrome

Most Recent Events

  • 23 Jan 2017 Preclinical trials in Bronchiolitis Obliterans in USA (unspecified route) before January 2017
  • 23 Jan 2017 Uteroglobin receives Orphan Drug status for Bronchiolitis Obliterans in European Union
  • 02 Jun 2016 Uteroglobin receives Rare Paediatric Disease Designation from the FDA for bronchopulmonary dysplasia and chronic respiratory morbidity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top